HALO
Halozyme Therapeutics is a biopharmaceutical company that develops and commercializes drug delivery technologies, primarily ENHANZE, a proprietary enzyme technology combining rHuPH20 that facilitates subcutaneous delivery of monoclonal antibodies, biologics, and small molecules across multiple therapeutic areas including oncology, immunology, and infectious disease through licensing partnerships with major pharmaceutical companies like Roche, Takeda, Pfizer, Janssen, and AbbVie. The company also develops Hypercon microparticle technology and Surf Bio hyperconcentration technology for high-concentration biologic delivery, operates commercial proprietary products including Hylenex and XYOSTED, and earns royalties from ten approved partner products already on the market. Halozyme's ENHANZE collaborations generate upfront fees, milestone payments, bulk rHuPH20 sales, and royalties,